2.15 USD
+0.03 (+1.42%)
Last: Feb 6, 2026, 05:20 PM
We assign a fundamental rating of 3 out of 10 to KPRX. KPRX was compared to 191 industry peers in the Pharmaceuticals industry. The financial health of KPRX is average, but there are quite some concerns on its profitability. While showing a medium growth rate, KPRX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- KPRX had negative earnings in the past year.
- KPRX had a negative operating cash flow in the past year.
- KPRX had negative earnings in 4 of the past 5 years.
- KPRX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -28.60%, KPRX perfoms like the industry average, outperforming 53.40% of the companies in the same industry.
- KPRX has a Return On Equity (-38.12%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.6% | ||
| ROE | -38.12% | ||
| ROIC | N/A |
ROA(3y)-52.66%
ROA(5y)-55.95%
ROE(3y)-106.19%
ROE(5y)-105.72%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- KPRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- KPRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- KPRX has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, KPRX has more shares outstanding
- There is no outstanding debt for KPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -6.38, we must say that KPRX is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -6.38, KPRX is not doing good in the industry: 64.92% of the companies in the same industry are doing better.
- KPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.38 |
ROIC/WACCN/A
WACC9.45%
2.3 Liquidity
- KPRX has a Current Ratio of 8.79. This indicates that KPRX is financially healthy and has no problem in meeting its short term obligations.
- KPRX has a better Current ratio (8.79) than 75.92% of its industry peers.
- A Quick Ratio of 8.79 indicates that KPRX has no problem at all paying its short term obligations.
- KPRX has a Quick ratio of 8.79. This is in the better half of the industry: KPRX outperforms 76.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.79 | ||
| Quick Ratio | 8.79 |
3. Growth
3.1 Past
- KPRX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.79%.
- The Revenue for KPRX has decreased by -100.00% in the past year. This is quite bad
- The Revenue has been growing by 42.88% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)2.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.23%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y42.88%
Sales Q2Q%N/A
3.2 Future
- Based on estimates for the next years, KPRX will show a very strong growth in Earnings Per Share. The EPS will grow by 40.29% on average per year.
- KPRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 32.09% yearly.
EPS Next Y-267.71%
EPS Next 2Y-104.62%
EPS Next 3Y-59.01%
EPS Next 5Y40.29%
Revenue Next Year-91.05%
Revenue Next 2Y-70.08%
Revenue Next 3Y-25.99%
Revenue Next 5Y32.09%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for KPRX. In the last year negative earnings were reported.
- Also next year KPRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as KPRX's earnings are expected to decrease with -59.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-104.62%
EPS Next 3Y-59.01%
5. Dividend
5.1 Amount
- KPRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:KPRX (2/6/2026, 5:20:02 PM)
2.15
+0.03 (+1.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2025-11-07/bmo
Earnings (Next)03-23 2026-03-23/amc
Inst Owners19.58%
Inst Owner Change1.53%
Ins Owners2.84%
Ins Owner Change0%
Market Cap7.91M
Revenue(TTM)N/A
Net Income(TTM)-8.54M
Analysts82.86
Price Target12.24 (469.3%)
Short Float %0.72%
Short Ratio0.52
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)56.91%
Min EPS beat(2)12.49%
Max EPS beat(2)101.33%
EPS beat(4)3
Avg EPS beat(4)13.09%
Min EPS beat(4)-85.38%
Max EPS beat(4)101.33%
EPS beat(8)5
Avg EPS beat(8)92.77%
EPS beat(12)8
Avg EPS beat(12)57.86%
EPS beat(16)9
Avg EPS beat(16)28.57%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9.09%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.67%
EPS NY rev (1m)0%
EPS NY rev (3m)32.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.35 | ||
| P/tB | 0.5 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.09
EYN/A
EPS(NY)-2.27
Fwd EYN/A
FCF(TTM)-2.72
FCFYN/A
OCF(TTM)-2.73
OCFYN/A
SpS0
BVpS6.09
TBVpS4.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.6% | ||
| ROE | -38.12% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-52.66%
ROA(5y)-55.95%
ROE(3y)-106.19%
ROE(5y)-105.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 61.39% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.79 | ||
| Quick Ratio | 8.79 | ||
| Altman-Z | -6.38 |
F-Score1
WACC9.45%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.23%
EPS Next Y-267.71%
EPS Next 2Y-104.62%
EPS Next 3Y-59.01%
EPS Next 5Y40.29%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y42.88%
Sales Q2Q%N/A
Revenue Next Year-91.05%
Revenue Next 2Y-70.08%
Revenue Next 3Y-25.99%
Revenue Next 5Y32.09%
EBIT growth 1Y-216.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.13%
OCF growth 3YN/A
OCF growth 5YN/A
KIORA PHARMACEUTICALS INC / KPRX FAQ
What is the ChartMill fundamental rating of KIORA PHARMACEUTICALS INC (KPRX) stock?
ChartMill assigns a fundamental rating of 3 / 10 to KPRX.
What is the valuation status for KPRX stock?
ChartMill assigns a valuation rating of 0 / 10 to KIORA PHARMACEUTICALS INC (KPRX). This can be considered as Overvalued.
How profitable is KIORA PHARMACEUTICALS INC (KPRX) stock?
KIORA PHARMACEUTICALS INC (KPRX) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for KPRX stock?
The Earnings per Share (EPS) of KIORA PHARMACEUTICALS INC (KPRX) is expected to decline by -267.71% in the next year.